Brief: Allena Pharmaceuticals Provides Clinical And Corporate Update

Allena Pharmaceuticals

04/01/2022 10:10

Jan 4 (Reuters) - Allena Pharmaceuticals Inc  ALNA.O :
    * ALLENA PHARMACEUTICALS PROVIDES CLINICAL AND CORPORATE
UPDATE
    * ALLENA PHARMACEUTICALS- ALLN-346 PHASE 2A STUDY 202
ACTIVELY
ENROLLING PATIENTS WITH GOUT, STAGES 2 AND 3 CHRONIC KIDNEY
DISEASE IN PARALLEL COHORTS
    * ALLN-346 DEMONSTRATES STATISTICALLY SIGNIFICANT REDUCTION
IN
SERUM URIC ACID AND A WELL-TOLERATED SAFETY PROFILE
    * COMPANY HAS INITIATED A PROCESS TO EXPLORE A RANGE OF
STRATEGIC
AND FINANCING ALTERNATIVES
    * DATA FROM ALLN-346 PHASE 2A STUDY 202, STAGE 1 AND STAGE 2
COHORTS EXPECTED IN Q1 2022
    * ALLENA PHARMACEUTICALS - EXPECTS THAT CASH AND EQUIVALENTS
TO BE
SUFFICIENT TO FUND CURRENT OPERATIONAL PLAN THROUGH Q1 2022
    * ALLENA PHARMACEUTICALS - POTENTIAL STRATEGIC ALTERNATIVES
THAT
MAY BE EVALUATED INCLUDE PARTNERSHIPS FOR EITHER OR BOTH OF CO'S
DEVELOPMENT CANDIDATES
    * ALLENA PHARMACEUTICALS - POTENTIAL STRATEGIC ALTERNATIVES
INCLUDE SALE OF ONE OR BOTH OF DEVELOPMENT CANDIDATES, A SALE OR
MERGER OF CO
    * ALLENA PHARMACEUTICALS - NO ASSURANCE THAT THIS STRATEGIC
REVIEW
PROCESS WILL RESULT IN THE COMPANY PURSUING ANY TRANSACTION OR
THAT ANY TRANSACTION
    * HAS NOT SET A TIMETABLE FOR COMPLETION OF THIS STRATEGIC
REVIEW
PROCESS
    * CURRENTLY EVALUATING POTENTIAL MODIFICATIONS TO PIVOTAL
URIROX-2
PHASE 3 TRIAL OF RELOXALIASE IN ENTERIC HYPEROXALURIA

Source text for Eikon:  ID:nGNX1VVT8m 
Further company coverage:  ALNA.O 

 ((Reuters.Briefs@thomsonreuters.com;))